Q97824616

Summary

Q97824616 is a committee group motion^[1].

Key Facts

• Q97824616 authored Thomas Nihlén^[2].
• Q97824616 authored Gunvor G. Ericson^[3].
• Q97824616 authored Jan Lindholm^[4].
• Q97824616 authored Bodil Valero^[5].
• Q97824616 authored Peter Rådberg^[6].
• Q97824616 authored Mats Pertoft^[7].
• Q97824616's instance of is recorded as committee group motion^[8].
• Q97824616's part of the series is recorded as motions of the 2009-2010 legislative session of the Riksdag^[9].
• Q97824616's language of work or name is recorded as Swedish^[10].
• Q97824616 was released on +2009-09-24T00:00:00Z^[11].
• Q97824616's main subject is medication^[12].
• Q97824616's main subject is Swedish Medical Products Agency^[13].
• Q97824616's work available at URL is recorded as http://data.riksdagen.se/dokument/GX02So220^[14].
• Q97824616's work available at URL is recorded as http://data.riksdagen.se/dokumentstatus/GX02So220^[15].
• Q97824616's applies to jurisdiction is recorded as Sweden^[16].
• Q97824616's legal citation of this text is recorded as Mot. 2009/10:So220^[17].
• Q97824616's title is recorded as Läkemedelsverkets finansiering^[18].
• Q97824616's cites work is recorded as Q98410267^[19].
• Q97824616's maintained by WikiProject is recorded as Project Riksdagen's documents^[20].
• Q97824616's copyright status is recorded as public domain^[21].
• Q97824616's legislative committee is recorded as Committee on Health and Welfare^[22].

Body

Definition and Type

Q97824616's instance of is recorded as committee group motion^[8].